Human Organoids Market by Product (Liver, Kidney, Pancreatic Models (2D, 3D)), Disease Area (Oncology, GI, Neurological Disorders), Application (Drug Toxicity, Personalized Medicine), End User (Pharma & Biotech Companies, CROs) - Global Forecast to 2029
인간 오가노이드 시장 규모는 2024년 11억 9,000만 달러에서 2029년 23억 3,000만 달러로 증가하여 예측 기간 동안 연평균 14.4%의 성장률을 보일 것으로 예상됩니다.
| 조사 범위 |
| 조사 대상 연도 |
2022-2029년 |
| 기준 연도 |
2023년 |
| 예측 기간 |
2024-2029년 |
| 검토 단위 |
금액(달러) |
| 부문별 |
제품별, 유래별, 유형별, 배양 방법별, 질병영역별, 용도별, 최종사용자별, 지역별 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카, GCC 국가 |
인간 오가노이드 연구에 대한 자금 지원이 증가하면 연구 능력이 크게 향상되고 응용 범위가 확대되어 유기체 시장의 성장을 직접적으로 촉진할 수 있습니다. 자금 지원은 과학자들이 암, 신경 퇴행성 질환, 의약품 개발 등 다양한 분야에서 오가노이드를 연구하게 하고, 제약회사와 생명공학 기업들이 모여들게 할 것입니다. 오가노이드 기술이 더 상용화되고 명확한 규제 프레임워크가 마련되면 시장 접근이 더욱 쉬워질 것으로 예상됩니다. 이는 전 세계 인간 유래 유기체 시장의 성장을 촉진하고 있습니다. 인간 오가노이드에 대한 관심이 높아짐에 따라 시장 잠재력은 크지만, 숙련된 인력이 부족합니다. 혁신적인 오가노이드 기술에 대한 수요가 증가함에 따라, 이러한 복잡한 모델을 개발하고 사용할 수 있는 자격을 갖춘 인력이 부족하여 지속적인 연구개발과 상용화를 위한 노력에 어려움을 겪고 있습니다.
인간 오가노이드 시장은 용도별로 발생생물학, 약물 독성 및 유효성 시험, 질병 병리, 맞춤의료, 재생의료, 기타 용도에 따라 분류됩니다. 인간 오가노이드는 인간 고유의 발생생물학 및 질병에 이르는 과정을 연구하는 데 있어 본질적으로 훨씬 더 윤리적이고 효율적인 대안이 될 수 있습니다. 따라서 특히 발생생물학을 전문으로 하는 학술 및 연구 센터에서 그 적용이 활발히 진행되고 있습니다.
최종사용자별로 보면 인간 오가노이드 시장은 제약 및 생명공학 기업, CRO, 학술 및 연구기관, 기타 최종사용자로 구분됩니다. 제약 및 생명공학 기업 부문은 신약 개발, 질병 모델링, 맞춤형 의료에 오가노이드를 사용하는 연구개발 활동이 활발해지면서 인간 오가노이드 시장에서 가장 높은 CAGR로 성장할 것으로 예상됩니다. 이들 기업은 신약 개발, 약물 효능 및 독성 테스트, 세포 수준에서 복잡한 질병에 대한 인사이트를 얻기 위해 오가노이드를 사용하고 있습니다.
이 보고서는 세계 인간 오가노이드 시장을 조사하여 제품별, 유래별, 유형별, 배양 방법별, 질병 영역별, 용도별, 최종사용자별, 지역별 동향, 시장 진입 기업 개요 등을 정리했습니다.
목차
제1장 소개
제2장 조사 방법
제3장 주요 요약
제4장 주요 인사이트
제5장 시장 개요
- 소개
- 시장 역학
- 가격 분석
- 특허 분석
- 밸류체인 분석
- 공급망 분석
- 무역 분석
- 생태계 분석
- Porter's Five Forces 분석
- 주요 이해관계자와 구입 기준
- 규제 상황
- 기술 분석
- 2024-2025년의 주요 회의와 이벤트
- 고객의 비즈니스에 영향을 미치는 동향/혼란
- 투자와 자금 조달 시나리오
- 사례 연구 분석
- 인간 오가노이드 시장의 AI의 영향
제6장 인간 오가노이드 시장(제품별)
- 소개
- 간 모델
- 신장 모델
- 췌장 모델
- 대장 모델
- 심장 모델
- 폐 모델
- 기타 제품
제7장 인간 오가노이드 시장(유래별)
- 소개
- 성체줄기세포
- 유도 만능줄기세포
- 배아줄기세포
- 기타
제8장 인간 오가노이드 시장(유형별)
제9장 인간 오가노이드 시장(배양 방법별)
- 소개
- 매트리겔 매트릭스 배양
- 기액 계면 배양
- 현탁 배양법
- 3D 바이오프린팅 배양
- 기타
제10장 인간 오가노이드 시장(질환 영역별)
- 소개
- 종양
- 간질환
- 위장질환
- 심혈관질환
- 감염증
- 신경질환
- 기타
제11장 인간 오가노이드 시장(용도별)
- 소개
- 발생생물학
- 약물 독성 및 유효성 시험
- 질병 병리학
- 맞춤형 의료
- 재생의료
- 기타
제12장 인간 오가노이드 시장(최종사용자별)
- 소개
- 제약·바이오테크놀러지 기업
- CRO
- 학술연구기관
- 기타
제13장 인간 오가노이드 시장(지역별)
- 소개
- 북미
- 유럽
- 유럽의 거시경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타
- 아시아태평양
- 아시아태평양의 거시경제 전망
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타
- 라틴아메리카
- 라틴아메리카의 거시경제 전망
- 브라질
- 멕시코
- 기타
- 중동 및 아프리카
- 삶의 질 향상에 대한 관심이 상승, 시장을 견인
- 중동 및 아프리카의 거시경제 전망
- GCC 국가
- 시장 확대를 향한 첨단 의료 인프라에 대한 주목 상승
- GCC 국가의 거시경제 전망
제14장 경쟁 구도
- 소개
- 주요 진출 기업 전략/강점
- 매출 분석, 2021-2023년
- 시장 점유율 분석, 2023년
- 기업 평가 매트릭스 : 주요 진출 기업, 2023년
- 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
- 기업 가치 평가와 재무 지표
- 브랜드/제품 비교 분석
- 경쟁 시나리오
제15장 기업 개요
- 주요 진출 기업
- THERMO FISHER SCIENTIFIC INC.
- CORNING INCORPORATED
- MERCK KGAA
- BIOIVT
- HUB ORGANOIDS BV
- BICO
- BECYTES BIOTECHNOLOGIES
- INSPHERO
- GBA GROUP
- KIRKSTALL LTD.
- MIMETAS BV
- NEUROMICS
- PRIMACYT CELL CULTURE TECHNOLOGY GMBH
- STEMCELL TECHNOLOGIES
- 기타 기업
- ACROBIOSYSTEMS
- BIOPREDIC INTERNATIONAL
- CN BIO INNOVATIONS LTD.
- CYPRIO
- EMULATE, INC.
- KERAFAST, INC.
- PANDORUM TECHNOLOGIES PVT. LTD.
- CYFUSE BIOMEDICAL KK
- NEYROBLASTGX LLC
- 3DNAMICS INC.
- DEFINIGEN LIMITED
제16장 부록
ksm
The value of the human organoids market will increase from an estimated USD 1.19 billion in 2024 to USD 2.33 billion in 2029, at a CAGR of 14.4% through the forecast period.
| Scope of the Report |
|---|
| Years Considered for the Study | 2022-2029 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Units Considered | Value (USD) |
| Segments | By Product, Source, type, Culture Method, Disease Area, Application, and End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries |
Advancement in funding for research in human organoids directly promotes the growth of the market for organoids with significant improvement in research capabilities and increases the scope of applications. Financial support brings scientists to explore organoids in various fields, such as cancer, neurodegenerative diseases, and drug development, which attracts pharmaceutical and biotech companies. A more commercialized version of the organoid technologies along with a clear regulatory framework will even further ease access to the market. This, in turn, is fuelling the growth of the global human organoids market. Although the growing interest in human organoids provides a major market potential, there is a dearth of skilled labor. With such increasing demand in innovative organoid technology, the shortage of qualified personnel who are able to develop and use such complex models has become a challenge to the continued research and commercialization effort.
"Developmental biology segment is expected to have the fastest growth rate in the human organoids market, by application, during the forecast period."
The human organoids market is segmented into developmental biology, drug toxicity & efficacy testing, disease pathology, personalized medicine, regenerative medicine, and other applications, based on application. Human organoids represent an essentially much more ethically compliant and efficient alternative to studying human-specific developmental biology and the processes leading to disease. It is therefore increasingly being applied, especially in academic and research centers specializing in developmental biology.
"Pharmaceutical & biotechnology companies segment accounted for the highest growth rate in the human organoids market, by end user, during the forecast period."
Based on end user, the human organoids market is bifurcated into into pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and other end users. The pharmaceutical and biotechnology companies segment is expected to grow at the highest CAGR in the market of human organoids mainly due to their intense research and development activities, where they use organoids in drug discovery, disease modeling, and personalized medicine. These companies employ organoids in developing new drugs and testing them for the efficacy and toxicity of the drug, besides gaining insights into the complexities of a diseaseat a cellular level.
"Asia Pacific: The fastest-growing region in human organoids market."
The worldwide market for human organoids is categorized into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. Notably, the Asia-Pacific region marks the highest CAGR in the human organoids market, due to increasing investments into healthcare infrastructure and research that advance the capabilities of medical facilities. In addition to this, the number of rapidly aging patients strongly demands effective treatments for diseases related to age. Consequently, human organoids act as great models for the study of such conditions. The growing medical tourism activities in the APAC region also happen to be of great influence for the market, given the rapid increase of patients seeking advanced treatments and high-class healthcare services. These factors, collectively, have put the APAC region on a growth trajectory for human organoids markets.
The break-up of the profile of primary participants in the human organoids market:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%
The key players in this market are Thermo Fisher Scientific Inc. (US), Corning Incorporated (US), Merck KGaA (Germany), BioIVT (US), HUB Organoids BV (Netherlands), BICO (Sweden), BeCytes Biotechnologies SL (Spain), InSphero (Switzerland), GBA Group (Germany), Kirkstall Ltd. (UK), MIMETAS BV (Netherlands), Neuromics (US), PRIMACYT Cell Culture Technology GmbH (Germany), STEMCELL Technologies (Canada), ACROBiosystems (China), Biopredic International (France), CN Bio Innovations Ltd. (UK), CYPRIO (France), Emulate, Inc. (US), Kerafast, Inc. (US), Pandorum Technologies Pvt. Ltd (India), CYFUSE BIOMEDICAL K.K. (Japan), NeyroblastGX LLC (US), 3Dnamics Inc. (US), and DefiniGEN Limited (UK).
Research Coverage:
This research report categorizes the human organoids market by product (Liver models, kidney models, pancreatic models, colorectal models, heart models, lung models, other products), by source (adult stem cells, induced pluripotent stem cells, embryonic stem cells, other sources), by type (ready-to-use products, customizable products), by culture method (air-liquid interface culture, suspension culture, matrigel matrix culture, 3d bioprinting culture, and other culture methods), by disease area (oncology, liver diseases, gastrointestinal diseases, cardiovascular diseases, infectious diseases, neurological disorders, and other disease areas), by apllication (developmental biology, drug toxicity & efficacy testing, disease pathology, personalized medicine, regenerative medicine, and other applications), by end user (pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the human organoids market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the human organoids market. Competitive analysis of upcoming startups in the human organoids market ecosystem is covered in this report.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall human organoids market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Growing focus on developing alternatives to animal testing, rising R&D funding and venture capital investments, increasing research on organoids, increasing prevalence of non-alcoholic fatty liver disease , and need for early detection of drug toxicity to minimize financial losses caused by late-stage drug failure), opportunities (Increasing focus on drug discovery activities, rising demand for organ transplantation, and growth opportunities in emerging economies), restraints (Issues related to incorporating organoids into existing workflows), and challenges (Dearth of skilled professionals) influencing the growth of the human organoids market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the human organoids market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the human organoids market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the human organoids market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Thermo Fisher Scientific Inc. (US), Corning Incorporated (US), Merck KGaA (Germany), BioIVT (US), and HUB Organoids BV (Netherlands).
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKETS COVERED & REGIONAL SCOPE
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.2 RESEARCH APPROACH
- 2.2.1 SECONDARY DATA
- 2.2.1.1 Key data from secondary sources
- 2.2.2 PRIMARY DATA
- 2.2.2.1 Primary sources
- 2.2.2.2 Key data from primary sources
- 2.2.2.3 Key industry insights
- 2.2.2.4 Breakdown of primary interviews
- 2.3 MARKET SIZE ESTIMATION
- 2.3.1 BOTTOM-UP APPROACH
- 2.3.1.1 Approach 1: Company revenue estimation approach
- 2.3.1.2 Approach 2: Presentations of companies and primary interviews
- 2.3.1.3 Growth forecasts
- 2.3.1.4 CAGR projections
- 2.3.2 TOP-DOWN APPROACH
- 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
- 2.5 MARKET SHARE
- 2.6 ASSUMPTIONS & LIMITATIONS
- 2.6.1 STUDY ASSUMPTIONS
- 2.6.2 GROWTH RATE ASSUMPTIONS
- 2.6.3 LIMITATIONS
- 2.7 RISK ASSESSMENT
- 2.7.1 RISK ASSESSMENT: HUMAN ORGANOIDS MARKET
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 HUMAN ORGANOIDS MARKET OVERVIEW
- 4.2 HUMAN ORGANOIDS MARKET, BY PRODUCT, 2024 VS. 2029
- 4.3 HUMAN ORGANOIDS MARKET, BY SOURCE, 2024 VS. 2029
- 4.4 HUMAN ORGANOIDS MARKET, BY TYPE, 2024 VS. 2029
- 4.5 HUMAN ORGANOIDS MARKET, BY APPLICATION, 2024 VS. 2029
- 4.6 HUMAN ORGANOIDS MARKET, BY END USER, 2024 VS. 2029
- 4.7 HUMAN ORGANOIDS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Growing focus on developing alternatives to animal testing
- 5.2.1.2 Rising R&D funding and venture capital investments
- 5.2.1.3 Increasing research on organoids
- 5.2.1.4 Increasing prevalence of non-alcoholic fatty liver disease
- 5.2.1.5 Need for early detection of drug toxicity to minimize financial losses caused by late-stage drug failure
- 5.2.2 RESTRAINTS
- 5.2.2.1 Issues related to incorporating organoids into existing workflows
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Increasing focus on drug discovery activities
- 5.2.3.2 Rising demand for organ transplantation
- 5.2.3.3 Growth opportunities in emerging economies
- 5.2.4 CHALLENGES
- 5.2.4.1 Dearth of skilled professionals
- 5.3 PRICING ANALYSIS
- 5.3.1 AVERAGE SELLING PRICE, BY PRODUCT
- 5.3.2 AVERAGE SELLING PRICE, BY REGION
- 5.4 PATENT ANALYSIS
- 5.4.1 LIST OF MAJOR PATENTS
- 5.5 VALUE CHAIN ANALYSIS
- 5.6 SUPPLY CHAIN ANALYSIS
- 5.7 TRADE ANALYSIS
- 5.7.1 IMPORT DATA (HS CODE 3002)
- 5.7.2 EXPORT DATA (HS CODE 3002)
- 5.8 ECOSYSTEM ANALYSIS
- 5.9 PORTER'S FIVE FORCES ANALYSIS
- 5.9.1 THREAT OF NEW ENTRANTS
- 5.9.2 THREAT OF SUBSTITUTES
- 5.9.3 BARGAINING POWER OF BUYERS
- 5.9.4 BARGAINING POWER OF SUPPLIERS
- 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.10.2 KEY BUYING CRITERIA
- 5.11 REGULATORY LANDSCAPE
- 5.11.1 KEY REGULATIONS
- 5.11.1.1 North America
- 5.11.1.1.1 US
- 5.11.1.1.2 Canada
- 5.11.1.2 Europe
- 5.11.1.3 Asia Pacific
- 5.11.1.3.1 China
- 5.11.1.3.2 Japan
- 5.11.1.3.3 India
- 5.11.1.4 Latin America
- 5.11.1.4.1 Brazil
- 5.11.1.4.2 Mexico
- 5.11.1.5 Middle East & Africa
- 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.11.2.1 North America
- 5.11.2.2 Europe
- 5.11.2.3 Asia Pacific
- 5.11.2.4 Latin America
- 5.11.2.5 Rest of the world
- 5.12 TECHNOLOGY ANALYSIS
- 5.12.1 KEY TECHNOLOGIES
- 5.12.1.1 Stem Cell Technology
- 5.12.2 COMPLEMENTARY TECHNOLOGIES
- 5.12.3 ADJACENT TECHNOLOGIES
- 5.13 KEY CONFERENCES AND EVENTS IN 2024-2025
- 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
- 5.15 INVESTMENT AND FUNDING SCENARIO
- 5.16 CASE STUDY ANALYSIS
- 5.16.1 CASE STUDY 1: EVALUATION OF PATIENT-DERIVED ORGANOIDS FOR DRUG SENSITIVITY TESTING IN METASTATIC COLORECTAL CANCER WITH LIMITED TREATMENT OPTIONS
- 5.16.2 CASE STUDY 2: DEVELOPING STABLE ORGANOID MODELS FROM GASTRIC CANCER TISSUES FOR PERSONALIZED MEDICINE AND DRUG SCREENING
- 5.16.3 CASE STUDY 3: OPTIMAL CULTIVATION PERIODS FOR BLADDER CANCER ORGANOIDS BASED ON TRANSCRIPTOMIC PLASTICITY
- 5.17 IMPACT OF AI ON HUMAN ORGANOIDS MARKET
6 HUMAN ORGANOIDS MARKET, BY PRODUCT
- 6.1 INTRODUCTION
- 6.2 LIVER MODELS
- 6.2.1 2D LIVER MODELS
- 6.2.1.1 Fresh hepatocytes
- 6.2.1.1.1 Increased drug metabolism studies to drive market
- 6.2.1.2 Cryopreserved hepatocytes
- 6.2.1.2.1 High quality and response to support market growth
- 6.2.1.3 Other 2D liver models
- 6.2.2 3D LIVER MODELS
- 6.2.2.1 Liver organoids
- 6.2.2.1.1 Support for determining pharmacology and hepatic toxicity of drugs to treat NAFLD
- 6.2.2.2 3D bioprinted liver models
- 6.2.2.2.1 Increased use in drug discovery to propel market growth
- 6.2.2.3 Liver spheroids
- 6.2.2.3.1 Need for better approaches in drug discovery to promote adoption of spheroids
- 6.2.2.4 Liver-on-a-chip
- 6.2.2.4.1 Stricter regulations on animal testing to promote adoption of in vitro systems like liver-on-a-chip
- 6.2.2.5 Other 3D liver models
- 6.3 KIDNEY MODELS
- 6.3.1 2D KIDNEY MODELS
- 6.3.1.1 Fresh kidney cells
- 6.3.1.1.1 Accurate representation and functionality to support usage
- 6.3.1.2 Cryopreserved kidney cells
- 6.3.1.2.1 Long-term storage benefits to drive market
- 6.3.1.3 Other 2D kidney models
- 6.3.2 3D KIDNEY MODELS
- 6.3.2.1 Kidney organoids
- 6.3.2.1.1 Increasing incidence of chronic kidney disease to boost market growth
- 6.3.2.2 3D bioprinted kidney models
- 6.3.2.2.1 High cost of bioprinting to hinder market growth
- 6.3.2.3 Kidney spheroids
- 6.3.2.3.1 Feasibility of studying challenging kidney diseases to drive adoption
- 6.3.2.4 Other 3D kidney models
- 6.4 PANCREATIC MODELS
- 6.4.1 2D PANCREATIC MODELS
- 6.4.1.1 Fresh pancreatic cells
- 6.4.1.1.1 High responsiveness to stimuli to support demand
- 6.4.1.2 Cryopreserved pancreatic cells
- 6.4.1.2.1 Potential use of cryopreserved cells in regenerative therapies and transplantation to increase demand
- 6.4.1.3 Other 2D pancreatic models
- 6.4.2 3D PANCREATIC MODELS
- 6.4.2.1 Pancreatic organoids
- 6.4.2.1.1 Increasing prevalence of diabetes and pancreatic cancer to drive uptake of pancreatic organoids
- 6.4.2.2 3D bioprinted pancreatic models
- 6.4.2.2.1 Precise fabrication and close resemblance to native architecture to drive adoption
- 6.4.2.3 Pancreatic spheroids
- 6.4.2.3.1 Improved methods for 3D cell culture to promote spheroid formation and support market growth
- 6.4.2.4 Other 3D pancreatic models
- 6.5 COLORECTAL MODELS
- 6.5.1 2D COLORECTAL MODELS
- 6.5.1.1 Fresh colorectal cells
- 6.5.1.1.1 Increasing incidence of colorectal cancer worldwide to heighten demand for fresh cells
- 6.5.1.2 Cryopreserved colorectal cells
- 6.5.1.2.1 Ability to thaw and culture cells on demand to support efficient research process, reducing need for continuous tissue sourcing
- 6.5.1.3 Other 2D colorectal models
- 6.5.2 3D COLORECTAL MODELS
- 6.5.2.1 Colorectal organoids
- 6.5.2.1.1 Drive to enhance therapeutic interventions will support growth
- 6.5.2.2 3D bioprinted colorectal models
- 6.5.2.2.1 Increasing bioburden of colorectal cancer to drive market growth
- 6.5.2.3 Colorectal spheroids
- 6.5.2.3.1 Advantages in determining disease mechanisms and drug testing to drive adoption
- 6.5.2.4 Other 3D colorectal models
- 6.6 HEART MODELS
- 6.6.1 2D HEART MODELS
- 6.6.1.1 Fresh heart cells
- 6.6.1.1.1 Importance in regenerative medicine applications to support adoption
- 6.6.1.2 Cryopreserved heart cells
- 6.6.1.2.1 On-demand access for clinical or research use to drive uptake of cryopreserved cells
- 6.6.1.3 Other 2D heart models
- 6.6.2 3D HEART MODELS
- 6.6.2.1 Heart organoids
- 6.6.2.1.1 Rising demand in cardiogenesis research to propel market growth
- 6.6.2.2 3D bioprinted heart models
- 6.6.2.2.1 High production costs to hinder adoption
- 6.6.2.3 Heart spheroids
- 6.6.2.3.1 Challenges in controlling spheroid morphology to restrain growth
- 6.6.2.4 Other 3D heart models
- 6.7 LUNG MODELS
- 6.7.1 2D LUNG MODELS
- 6.7.1.1 Fresh lung cells
- 6.7.1.1.1 Use of fresh lung cells gaining momentum due to their ability to accurately replicate native lung environment
- 6.7.1.2 Cryopreserved lung cells
- 6.7.1.2.1 Advancements in slicing and cryopreservation to enable creation of thousands of hPCLS from a single lung
- 6.7.1.3 Other 2D lung models
- 6.7.2 3D LUNG MODELS
- 6.7.2.1 Lung organoids
- 6.7.2.1.1 Increased adoption in biological research areas to boost market growth
- 6.7.2.2 3D bioprinted lung models
- 6.7.2.2.1 Advancements in bioinks to support uptake of 3D bioprinted lung models
- 6.7.2.3 Lung spheroids
- 6.7.2.3.1 Advantages of physiologically relevant environments for evaluating drug efficacy and toxicity to support usage
- 6.7.2.4 Other 3D lung models
- 6.8 OTHER PRODUCTS
- 6.8.1 2D MODELS (OTHER PRODUCTS)
- 6.8.1.1 Fresh cells (other products)
- 6.8.1.1.1 New techniques for isolating and preserving fresh cells to help enhance quality of research
- 6.8.1.2 Cryopreserved cells (other products)
- 6.8.1.2.1 Long-term storage benefits and advancements in research to support adoption
- 6.8.1.3 Other 2D models
- 6.8.2 3D MODELS (OTHER PRODUCTS)
- 6.8.2.1 Organoids (other products)
- 6.8.2.1.1 Growing focus on collaboration fosters innovation in organoid development
- 6.8.2.2 3D bioprinted models (other products)
- 6.8.2.2.1 Lack of suitable bioinks for 3D bioprinting applications to hamper market growth
- 6.8.2.3 Spheroids (other products)
- 6.8.2.3.1 Predictive environment for assessing efficacy and safety to support adoption
- 6.8.2.4 Other 3D models (other products)
7 HUMAN ORGANOIDS MARKET, BY SOURCE
- 7.1 INTRODUCTION
- 7.2 ADULT STEM CELLS
- 7.2.1 ADULT STEM CELLS TO HOLD LARGEST SHARE OF MARKET, BY SOURCE
- 7.3 INDUCED PLURIPOTENT STEM CELLS
- 7.3.1 GROWING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE UPTAKE OF IPSCS
- 7.4 EMBRYONIC STEM CELLS
- 7.4.1 ETHICAL CONCERNS ASSOCIATED WITH ESCS TO HINDER MARKET GROWTH
- 7.5 OTHER SOURCES
8 HUMAN ORGANOIDS MARKET, BY TYPE
- 8.1 INTRODUCTION
- 8.2 READY-TO-USE PRODUCTS
- 8.2.1 MASS PRODUCTION OF READY-TO-USE PRODUCTS TO DRIVE ADOPTION
- 8.3 CUSTOMIZABLE PRODUCTS
- 8.3.1 ADVANCEMENTS IN 3D BIOPRINTING TO PROPEL MARKET GROWTH
9 HUMAN ORGANOIDS MARKET, BY CULTURE METHOD
- 9.1 INTRODUCTION
- 9.2 MATRIGEL MATRIX CULTURE
- 9.2.1 LONG-STANDING USE AND EFFECTIVENESS IN GROWING ORGANOIDS TO ENSURE ADOPTION
- 9.3 AIR-LIQUID INTERFACE CULTURE
- 9.3.1 INCREASING PREVALENCE OF DISEASES AFFECTING EPITHELIAL TISSUES TO DRIVE ADOPTION
- 9.4 SUSPENSION CULTURE
- 9.4.1 COST-EFFECTIVENESS OF SUSPENSION CULTURE TO DRIVE MARKET
- 9.5 3D BIOPRINTING CULTURE
- 9.5.1 RISING DEMAND FOR PERSONALIZED MEDICINE TO BOOST MARKET GROWTH
- 9.6 OTHER CULTURE METHODS
10 HUMAN ORGANOIDS MARKET, BY DISEASE AREA
- 10.1 INTRODUCTION
- 10.2 ONCOLOGY
- 10.2.1 GROWING FOCUS ON PERSONALIZED MEDICINE IN ONCOLOGY TO DRIVE DEMAND FOR CANCER ORGANOIDS
- 10.3 LIVER DISEASES
- 10.3.1 INCREASING INCIDENCE OF LIVER-RELATED CONDITIONS TO DRIVE DEMAND FOR EFFECTIVE RESEARCH MODELS
- 10.4 GASTROINTESTINAL DISEASES
- 10.4.1 WIDE USAGE IN MODELING INFLAMMATORY BOWEL DISEASE AND MALIGNANCIES TO PROPEL MARKET
- 10.5 CARDIOVASCULAR DISEASES
- 10.5.1 RISING INCIDENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
- 10.6 INFECTIOUS DISEASES
- 10.6.1 USE OF ORGANOIDS IN DEVELOPING ANTIVIRAL DRUGS TO SUPPORT MARKET GROWTH
- 10.7 NEUROLOGICAL DISORDERS
- 10.7.1 GROWING INCIDENCE OF NEUROPSYCHIATRIC DISORDERS TO FUEL UPTAKE OF HUMAN ORGANOIDS
- 10.8 OTHER DISEASE AREAS
11 HUMAN ORGANOIDS MARKET, BY APPLICATION
- 11.1 INTRODUCTION
- 11.2 DEVELOPMENTAL BIOLOGY
- 11.2.1 TECHNOLOGICAL ADVANCEMENTS IN STEM CELL RESEARCH TO BOOST MARKET GROWTH
- 11.3 DRUG TOXICITY & EFFICACY TESTING
- 11.3.1 INCREASED DRUG DEVELOPMENT COSTS TO DRIVE GROWTH
- 11.4 DISEASE PATHOLOGY
- 11.4.1 INCREASED DEMAND FOR ADVANCED IN VITRO DISEASE STUDIES TO AUGMENT MARKET GROWTH
- 11.5 PERSONALIZED MEDICINE
- 11.5.1 HIGH COST AND INSUFFICIENT DATA TO HAMPER MARKET GROWTH
- 11.6 REGENERATIVE MEDICINE
- 11.6.1 INCREASING FUNDING ACTIVITIES TO PROPEL MARKET GROWTH
- 11.7 OTHER APPLICATIONS
12 HUMAN ORGANOIDS MARKET, BY END USER
- 12.1 INTRODUCTION
- 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 12.2.1 INCREASING PREVALENCE OF CHRONIC DISEASES TO PROPEL MARKET GROWTH
- 12.3 CONTRACT RESEARCH ORGANIZATIONS
- 12.3.1 INCREASING OUTSOURCING OF CLINICAL RESEARCH SERVICES TO SUPPORT MARKET GROWTH
- 12.4 ACADEMIC & RESEARCH INSTITUTES
- 12.4.1 RISING GOVERNMENT FUNDING AND INCREASING INDUSTRY-ACADEMIA COLLABORATIONS TO DRIVE MARKET
- 12.5 OTHER END USERS
13 HUMAN ORGANOIDS MARKET, BY REGION
- 13.1 INTRODUCTION
- 13.2 NORTH AMERICA
- 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 13.2.2 US
- 13.2.2.1 Rising prevalence of chronic respiratory diseases and organ transplants to expedite growth
- 13.2.3 CANADA
- 13.2.3.1 Growing incidence of cancer and investments in disease diagnostics & life science research to drive market
- 13.3 EUROPE
- 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 13.3.2 GERMANY
- 13.3.2.1 Higher healthcare spending and organ transplants to favor market growth
- 13.3.3 UK
- 13.3.3.1 Rising disease prevalence to drive market growth
- 13.3.4 FRANCE
- 13.3.4.1 Increasing availability of advanced medical technologies to support market growth
- 13.3.5 ITALY
- 13.3.5.1 Modernization of healthcare infrastructure to support market
- 13.3.6 SPAIN
- 13.3.6.1 Rising incidences of cancer to drive demand
- 13.3.7 REST OF EUROPE
- 13.4 ASIA PACIFIC
- 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 13.4.2 CHINA
- 13.4.2.1 Healthcare infrastructure improvements to support market growth in China
- 13.4.3 JAPAN
- 13.4.3.1 Rising biomedical & medical research to support market growth
- 13.4.4 INDIA
- 13.4.4.1 Large patient population and developing healthcare sector to drive market
- 13.4.5 AUSTRALIA
- 13.4.5.1 Rising private and public funding for research activities to drive market
- 13.4.6 SOUTH KOREA
- 13.4.6.1 Favorable government policies to fuel market growth
- 13.4.7 REST OF ASIA PACIFIC
- 13.5 LATIN AMERICA
- 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 13.5.2 BRAZIL
- 13.5.2.1 Growing pharmaceuticals market and budget allocations to boost market
- 13.5.3 MEXICO
- 13.5.3.1 Booming medical tourism to support growth
- 13.5.4 REST OF LATIN AMERICA
- 13.6 MIDDLE EAST & AFRICA
- 13.6.1 GROWING FOCUS ON IMPROVING QUALITY OF LIFE TO DRIVE MARKET
- 13.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
- 13.7 GCC COUNTRIES
- 13.7.1 RISING FOCUS ON ADVANCED HEALTH INFRASTRUCTURE TO AUGMENT MARKET
- 13.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
14 COMPETITIVE LANDSCAPE
- 14.1 INTRODUCTION
- 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HUMAN ORGANOIDS MARKET
- 14.3 REVENUE ANALYSIS, 2021-2023
- 14.4 MARKET SHARE ANALYSIS, 2023
- 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 14.5.1 STARS
- 14.5.2 EMERGING LEADERS
- 14.5.3 PERVASIVE PLAYERS
- 14.5.4 PARTICIPANTS
- 14.5.5 COMPANY FOOTPRINT, KEY PLAYERS, 2023
- 14.5.5.1 Company footprint
- 14.5.5.2 Region footprint
- 14.5.5.3 Product footprint
- 14.5.5.4 Source footprint
- 14.5.5.5 Application footprint
- 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 14.6.1 PROGRESSIVE COMPANIES
- 14.6.2 RESPONSIVE COMPANIES
- 14.6.3 DYNAMIC COMPANIES
- 14.6.4 STARTING BLOCKS
- 14.6.5 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, 2023
- 14.7 COMPANY VALUATION AND FINANCIAL METRICS
- 14.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
- 14.8.1 BIOIVT
- 14.8.2 BECYTES BIOTECHNOLOGIES
- 14.9 COMPETITIVE SCENARIO
- 14.9.1 PRODUCT LAUNCHES
- 14.9.2 DEALS
15 COMPANY PROFILES
- 15.1 KEY PLAYERS
- 15.1.1 THERMO FISHER SCIENTIFIC INC.
- 15.1.1.1 Business overview
- 15.1.1.2 Products offered
- 15.1.1.3 Recent developments
- 15.1.1.3.1 Product launches
- 15.1.1.3.2 Deals
- 15.1.1.4 MnM view
- 15.1.1.4.1 Right to win
- 15.1.1.4.2 Strategic choices
- 15.1.1.4.3 Weaknesses and competitive threats
- 15.1.2 CORNING INCORPORATED
- 15.1.2.1 Business overview
- 15.1.2.2 Products offered
- 15.1.2.3 Recent developments
- 15.1.2.4 MnM view
- 15.1.2.4.1 Right to win
- 15.1.2.4.2 Strategic choices
- 15.1.2.4.3 Weaknesses and competitive threats
- 15.1.3 MERCK KGAA
- 15.1.3.1 Business overview
- 15.1.3.2 Products offered
- 15.1.3.3 Recent developments
- 15.1.3.3.1 Deals
- 15.1.3.3.2 Expansions
- 15.1.3.4 MnM view
- 15.1.3.4.1 Right to win
- 15.1.3.4.2 Strategic choices
- 15.1.3.4.3 Weaknesses and competitive threats
- 15.1.4 BIOIVT
- 15.1.4.1 Business overview
- 15.1.4.2 Products offered
- 15.1.4.3 Recent developments
- 15.1.4.4 MnM view
- 15.1.4.4.1 Right to win
- 15.1.4.4.2 Strategic choices
- 15.1.4.4.3 Weaknesses and competitive threats
- 15.1.5 HUB ORGANOIDS BV
- 15.1.5.1 Business overview
- 15.1.5.2 Products offered
- 15.1.5.3 Recent developments
- 15.1.5.4 MnM view
- 15.1.5.4.1 Right to win
- 15.1.5.4.2 Strategic choices
- 15.1.5.4.3 Weaknesses and competitive threats
- 15.1.6 BICO
- 15.1.6.1 Business overview
- 15.1.6.2 Products offered
- 15.1.6.3 Recent developments
- 15.1.6.3.1 Product launches
- 15.1.6.3.2 Deals
- 15.1.6.3.3 Other developments
- 15.1.7 BECYTES BIOTECHNOLOGIES
- 15.1.7.1 Business overview
- 15.1.7.2 Products offered
- 15.1.8 INSPHERO
- 15.1.8.1 Business overview
- 15.1.8.2 Products offered
- 15.1.8.3 Recent developments
- 15.1.9 GBA GROUP
- 15.1.9.1 Business overview
- 15.1.9.2 Products offered
- 15.1.9.3 Recent developments
- 15.1.10 KIRKSTALL LTD.
- 15.1.10.1 Business overview
- 15.1.10.2 Products offered
- 15.1.11 MIMETAS BV
- 15.1.11.1 Business overview
- 15.1.11.2 Products offered
- 15.1.11.3 Recent developments
- 15.1.11.3.1 Product launches
- 15.1.11.3.2 Deals
- 15.1.12 NEUROMICS
- 15.1.12.1 Business overview
- 15.1.12.2 Products offered
- 15.1.13 PRIMACYT CELL CULTURE TECHNOLOGY GMBH
- 15.1.13.1 Business overview
- 15.1.13.2 Products offered
- 15.1.14 STEMCELL TECHNOLOGIES
- 15.1.14.1 Business overview
- 15.1.14.2 Products offered
- 15.1.14.3 Recent developments
- 15.2 OTHER PLAYERS
- 15.2.1 ACROBIOSYSTEMS
- 15.2.2 BIOPREDIC INTERNATIONAL
- 15.2.3 CN BIO INNOVATIONS LTD.
- 15.2.4 CYPRIO
- 15.2.5 EMULATE, INC.
- 15.2.6 KERAFAST, INC.
- 15.2.7 PANDORUM TECHNOLOGIES PVT. LTD.
- 15.2.8 CYFUSE BIOMEDICAL KK
- 15.2.9 NEYROBLASTGX LLC
- 15.2.10 3DNAMICS INC.
- 15.2.11 DEFINIGEN LIMITED
16 APPENDIX
- 16.1 DISCUSSION GUIDE
- 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 16.3 CUSTOMIZATION OPTIONS
- 16.4 RELATED REPORTS
- 16.5 AUTHOR DETAILS
